Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. - Wikidata - wikimedia - TriplyDB

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins.

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins.

http://www.wikidata.org/entity/Q44022591

about

Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management.Amyloid diseases of the heart: current and future therapies Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosi Syncope in cardiac amyloidosis and chronic ischemic heart disease: A case report Implantable cardioverter defibrillators in patients with cardiac amyloidosis.Cardiac Amyloidosis Presenting as Recurrent Syncope Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up Cardiac amyloidosis responding to bortezomib: case report and review of literature.Troponin: the biomarker of choice for the detection of cardiac injury Robert Arthur Kyle, MD: a conversation with the editor.Amyloidosis: pathogenesis and new therapeutic options.Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Biochemical markers of myocyte injury in heart failure Current perspectives on cardiac amyloidosis.Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).Updates in cardiac amyloidosis: a review.Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management.Present and future biochemical markers for detection of acute coronary syndrome.Presentation and outcome of patients with systemic amyloidosis undergoing dialysis Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.Transthyretin Cardiac Amyloidosis in Black Americans Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs Troponin in hematologic oncology.Incidence, diagnosis and prognosis of cardiac amyloidosis.Cardiac amyloidosis: an approach to diagnosis and management.Cardiac amyloidosis: the heart of the matter.Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment.Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.Light chain amyloidosis 2012: a new era.Pathophysiology and treatment of systemic amyloidosis.Diagnosis and management of type II myocardial infarction: increased demand for a limited supply of evidence.Cardiotoxicity due to Chemotherapy: the Role of Biomarkers.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.The search for efficient diagnostic and prognostic biomarkers of heart failure.Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis.Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.

P2860

Q24531062-4A6E9E10-F429-477B-A5E2-33F1562A0EA0 Q27023836-7D9607F0-CB1C-4BEE-9954-3D8C2E8B82BA Q28069975-7D1D6960-6742-4CCC-8285-E771030CA254 Q28269814-98D1E5B3-0505-4D4E-98EF-191E8058300E Q30469018-9C3BA97D-BBA6-4B91-BB08-3473496BBB0D Q33160234-9A82ED97-C8F0-4C10-877B-B6FEFAE96DFE Q33162514-2FE15C7E-66DE-4521-9E76-B0FE70CD53DF Q33167105-810DA959-0070-4DBF-AF3C-1C92C525702C Q33439299-DECBD87E-988C-494D-A87C-E1ED51E7E98B Q33654026-F19218BE-F9F9-4B20-B913-3E1D9DEDEEB9 Q34117708-D0626FAC-3233-4421-A074-C5CE069D3C05 Q34145491-87D9D93C-E75D-40F9-89A5-F5BC6E586374 Q35111771-07DCA97B-4EB4-4D12-8070-AA680478DBFA Q35849610-17170F06-074F-4C4D-97F2-B3283AB8FD5C Q35887596-018DBC3B-43E3-46B2-8D0E-14CC8C928AE7 Q35964900-DEB9068F-2277-4819-83AC-6547E22D36FC Q36338381-59F10880-F357-4DB9-8D5D-F63D568A5C6E Q36366356-385CE9CD-5576-4D5E-8234-CA21D2530E08 Q36367005-4D156E1D-45AC-4D92-97A3-9AC957C1FA59 Q36624223-11A988FF-62CE-47B6-B121-5CBBDB1D0062 Q36666741-73B109BE-0DC5-48B3-A4BD-905C27EA4D12 Q36824706-BDC22683-EF1B-4AAC-B5E3-47A27ABB9C4A Q36910372-F1747D6D-903E-444B-9D70-5635E29E66EB Q36921392-29948D46-BEE1-4A0D-8646-C6C89AAA6056 Q36950813-4E1C7AF9-D4EA-4A7F-AA9C-999A347F2152 Q37071685-A8BA667E-8D8F-4CE1-8559-BD07124351C6 Q37399628-08B72E1C-1233-443A-B2E6-ED1BE0415059 Q37770112-F3F115D0-F1D9-445C-81D6-5A4AC4B9D89A Q37899075-36FA73ED-3348-4D24-A6B5-733E58955C03 Q37900401-DB46F4AD-6EDB-4B1C-B7DA-37EB12C82AF4 Q37999957-90B804C4-14D5-44B6-93D9-444EB4E0E686 Q38072108-37F97845-2F21-4FE3-AE06-DC9D990E82E3 Q38131710-068748E4-4B85-4C99-8260-B926E3222141 Q38332044-A706611D-1D79-4FC0-BF16-B94F72E576C0 Q38508938-B878C0C2-E5A4-4482-9D41-D26033F75716 Q38614967-B8611EA0-5AE3-463E-B19F-0975C6722CE4 Q38879246-D1A9F3BD-57A9-410B-8FD6-888E98B240D8 Q39272596-488B982A-149C-4E2B-8283-BB11A3E4EB5F Q40491689-C1D6EB7F-C447-4B0D-8347-BF38B41618AD Q41645533-2000D305-CD0F-4C64-98CA-96F563443A2F

P2860

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins.

http://www.wikidata.org/entity/Q44022591

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Survival in patients with prim ...... aised serum cardiac troponins.

@en

Survival in patients with prim ...... aised serum cardiac troponins.

@nl

type

label

Survival in patients with prim ...... aised serum cardiac troponins.

@en

Survival in patients with prim ...... aised serum cardiac troponins.

@nl

prefLabel

Survival in patients with prim ...... aised serum cardiac troponins.

@en

Survival in patients with prim ...... aised serum cardiac troponins.

@nl

P1433

Q44022591-393487C9-6C75-40EF-BED8-58DA8A5E47A0

P1476

Q44022591-42904989-6AD0-4D2E-8613-5A97B5BBB84A

P2093

Q44022591-1A01A4C1-166E-4BF4-B3FC-E0EBD6885F5E

Q44022591-1F7A4A00-8053-49AF-9A5F-5F8673749C8B

Q44022591-248059F6-D60F-45AA-A99E-7F5BA0D67750

Q44022591-A13BB96D-9937-4F3E-9325-9E1ED4DD6E96

Q44022591-CC2D5E19-32EE-450D-8461-D5169D68FF5C

Q44022591-D9D9056A-729B-4FFA-A60A-4344C7199693

P304

Q44022591-5C66A9F1-51A0-4287-AD07-EE608482EC12

P31

Q44022591-CDE6C3FF-8B6D-464E-A4EB-25831394520A

P356

Q44022591-F2CEC3E8-D046-4DF3-B869-8BD5B6B43A87

P407

Q44022591-D27884C3-C99F-4ACA-8DA9-0B4E5D0F81FC

P433

Q44022591-253361C9-512D-4C3D-B471-0202F4C09896

P478

Q44022591-98265053-5820-4090-A893-06F6DF342106

P50

Q44022591-962AC1EA-D7AE-4E50-80B6-D569F22A7161

Q44022591-A525302F-65B7-429D-9D81-B742774A49F7

Q44022591-AB40C72B-721B-4279-9A66-8AD5B7C812B9

P577

Q44022591-07FAB93C-8DB9-45B8-A6F0-D183906F410A

P698

Q44022591-D5BD059B-0F2D-4BC5-B90B-D417B43D21EC

P921

Q44022591-90EDC5F0-367A-46E0-8C7D-8041898CAF3A

P356

S0140-6736(03)13396-X

P1433

P1476

Survival in patients with prim ...... aised serum cardiac troponins.

@en

P2093

Allan S Jaffe

http://www.w3.org/2001/XMLSchema#string

Joseph P McConnell

http://www.w3.org/2001/XMLSchema#string

Krishnaswamy Chandrasekaran

http://www.w3.org/2001/XMLSchema#string

Mary F Burritt

http://www.w3.org/2001/XMLSchema#string

Terry M Therneau

http://www.w3.org/2001/XMLSchema#string

Wayne L Miller

http://www.w3.org/2001/XMLSchema#string

P304

1787-1789

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(03)13396-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

9371

http://www.w3.org/2001/XMLSchema#string

P478

361

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12781539

http://www.w3.org/2001/XMLSchema#string

P921